Matsumoto A M, Paulsen C A, Bremner W J
J Clin Endocrinol Metab. 1984 Nov;59(5):882-7. doi: 10.1210/jcem-59-5-882.
The relative roles of FSH and LH in the control of human spermatogenesis are not well established. We previously reported that supraphysiological doses of hCG can stimulate sperm production in gonadotropin-suppressed normal men despite prepubertal FSH levels. To determine whether more nearly physiological levels of human LH (hLH) also can stimulate spermatogenesis when FSH levels are suppressed, we administered hLH to normal men whose endogenous gonadotropin levels and sperm production were suppressed by exogenous testosterone enanthate (T). After a 3-month control period, 11 normal men received 200 mg T, im, weekly to suppress LH and FSH. T administration alone was continued for 3-4 months until 3 successive sperm concentrations (performed twice monthly) revealed azoospermia or severe oligospermia (sperm concentrations, less than 4 million/ml). Then, while continuing T, 4 of the 11 men (experimental subjects) simultaneously received 1100 IU hLH, sc, daily for 4-6 months to replace LH activity, leaving FSH activity suppressed. The effect on sperm production of the selective FSH deficiency produced by hLH plus T administration was determined. The remaining 7 men (control subjects) continued to receive T alone at the same dosage, without gonadotropin replacement, for an additional 6 months. In the four experimental subjects, sperm concentrations increased significantly from 0.7 +/- 0.7 million/ml (mean +/- SEM) during T treatment alone to 19 +/- 4 million/ml during hLH plus T administration (P less than 0.001). However, none of the men achieved sperm concentrations consistently in their own pretreatment range. Sperm motilities and morphologies were normal in all four subjects by the end of hLH plus T administration. In contrast, sperm concentrations in the seven control subjects remained suppressed (less than 3 million/ml) throughout the entire period of prolonged T administration alone. Serum LH bioactivity, determined monthly by in vitro mouse Leydig cell bioassay in all four experimental subjects, was markedly suppressed during T administration alone (120 +/- 10 ng/ml) compared to that during the control period (390 +/- 20 ng/ml; P less than 0.001). With the addition of hLH to T, LH bioactivity returned to control levels (400 +/- 40 ng/ml; P = NS compared to control value). Serum FSH levels determined monthly by RIA were reduced from 98 +/- 12 ng/ml during the control period to undetectable levels (less than 25 ng/ml) during the T alone and the hLH plus T periods (P less than 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)
促卵泡生成素(FSH)和促黄体生成素(LH)在控制人类精子发生过程中的相对作用尚未完全明确。我们之前报道过,超生理剂量的人绒毛膜促性腺激素(hCG)可刺激促性腺激素被抑制的正常男性产生精子,尽管其促卵泡生成素水平处于青春期前水平。为了确定当促卵泡生成素水平被抑制时,更接近生理水平的人促黄体生成素(hLH)是否也能刺激精子发生,我们对正常男性给予hLH,这些男性的内源性促性腺激素水平和精子产生因外源性庚酸睾酮(T)而受到抑制。在3个月的对照期后,11名正常男性每周接受200mg T,肌肉注射,以抑制LH和FSH。单独给予T持续3 - 4个月,直到连续3次精子浓度(每月进行2次检测)显示无精子症或严重少精子症(精子浓度低于400万/ml)。然后,在继续给予T的同时,11名男性中的4名(实验对象)每天皮下注射1100IU hLH,持续4 - 6个月以替代LH活性,而FSH活性仍被抑制。确定了hLH加T给药所产生的选择性FSH缺乏对精子产生的影响。其余7名男性(对照对象)继续以相同剂量单独接受T,不进行促性腺激素替代,持续6个月。在4名实验对象中,精子浓度从单独T治疗期间的0.7±0.7百万/ml(平均值±标准误)显著增加到hLH加T给药期间的19±4百万/ml(P<0.001)。然而,没有一名男性的精子浓度持续达到其治疗前的范围。在hLH加T给药结束时,所有4名实验对象的精子活力和形态均正常。相比之下,7名对照对象的精子浓度在单独延长T给药的整个期间一直被抑制(低于300万/ml)。在所有4名实验对象中每月通过体外小鼠睾丸间质细胞生物测定法测定的血清LH生物活性,与对照期(390±20ng/ml)相比,在单独给予T期间显著被抑制(120±10ng/ml;P<0.001)。在T中加入hLH后,LH生物活性恢复到对照水平(400±40ng/ml;与对照值相比P=无显著差异)。通过放射免疫分析法每月测定的血清FSH水平从对照期的98±12ng/ml降至单独T期和hLH加T期的不可检测水平(低于25ng/ml)(P<0.01)。(摘要截短至400字)